1. Optimizing the Treatment of Recurrent/Metastatic SCCHN

3. Introduction

4. Current Treatment Guidelines for Recurrent/Metastatic SCCHN

5. Definition of Patients "Unfit" for Platinum-Based Chemotherapy

6. Definition of Patients "Unfit" for Platinum-Based Chemotherapy (cont)

7. Current Treatment Guidelines for Recurrent/Metastatic SCCHN

8. Definition of First-line Recurrent/Metastatic Disease

9. In the Recurrent Setting…

10. State of Art: First-Line Systemic Treatment for Recurrent/Metastatic SCCHN

11. First-Line Randomized Trials in Recurrent/Metastatic SCCHN

12. Platinum-Based Chemotherapy Plus Cetuximab: EXTREME Trial

13. EXTREME Trial: Hazard Ratios for Death

14. EXTREME Trial: Hazard Ratios for Disease Progression

15. EXTREME Trial: Grade 3-4 AEs in the Safety Population

16. EXTREME: A Real Progress but …

17. Phase 2 Testing: Taxanes and Cetuximab

18. TPExtreme TRIAL DESIGN

19. The Challenge of Treating Elderly Patients

20. Potential Future Directions for Treatment of Elderly Patients with Recurrent/Metastatic SCCHN

21. Investigational Regimens for Treatment of Elderly Patients with Recurrent/Metastatic SCCHN

22. Metastatic/Recurrent SCCHN: Treatment Considerations

23. Current Treatment Guidelines for Recurrent/Metastatic SCCHN

24. Nivolumab for Recurrent SCCHN*: CheckMate 141

25. CheckMate 141: Treatment Effect on OS

26. Efficacy and Safety of Pembrolizumab in Recurrent/Metastatic SCCHN: KEYNOTE-012, a Phase 1b Study

27. KEYNOTE-012: Response Rates

28. KEYNOTE-040: Pembrolizumab vs Standard Treatment in Recurrent/Metastatic SCCHN

29. Recurrent/Metastatic SCCHN: Use of Single-Agent Chemotherapy in the Second-line and Beyond

30. First-Line Use of Anti-PD-1 Immunotherapy for SCCHN

31. The Impact of AEs on Treatment Choice

32. Conclusions

33. Conclusions (cont)

34. Abbreviations

35. Abbreviations (cont)